Prognostic significance of angiogenesis and ki-67, p53, and p21 expression: A population-based endometrial carcinoma study

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1382-1390

  Salvesen, Helga B ^a   Iversen, Ole Erik ^a   Akslen, Lars A ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL PROLIFERATION; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS;

EID: 0032896335     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1382     Document Type: Article

References (69)

1. Abeler VM, Kjørstad KE: Endometrial adenocarcinoma in Norway: A study of a total population. Cancer 67:3093-3103, 1991
2. Homsley H, Zaino R: Endometrial cancer: Prognostic factors. Semin Oncol 21:71-78, 1994
3. Rose PG: Endometrial carcinoma. N Engl J Med 335:640-649, 1996
4. Zaino R, Kurman RJ, Diana KL, et al: Pathologic models to predict outcome for women with endometrial carcinoma Cancer 77:1115-1121, 1996
5. Salvesen HB, Akslen LA, Iversen T, et al: Recurrence of endometrial carcinoma and the value of routine follow up. Br J Obstet Gynaecol 104:1302-1307, 1997
6. Rotman M, Aziz H, Halpern J, et al: Endometrial carcinoma: Influence of prognostic factors on radiation management. Cancer 71:1471-1479, 1993
7. Jacks T, Weinberg A: Cell-cycle control and its watchman Nature 381:643-644, 1996
8. Kinzler KW, Vogelstein B: Life (and death) in a malignant tumour. Nature 379:19-20, 1996
9. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
10. Gasparini G, Weidner N, Bevilacqua P, et al: Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12:454-466, 1994
11. Weidner N, Moore DH, Vartanian R: Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol 25:337-342, 1994
12. Ito K, Watanabe K, Nasim S, et al: Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 54:4667-4670, 1994
13. Fontanini G, Bigini D, Vignati S, et al: Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 177:57-63, 1995
14. Nordström B, Strang P, Bergström R, et al: A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Cancer 78:1942-1951, 1996
15. Aas T, Børresen AL, Geisler S, et al: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814, 1996
16. Barbareschi M, Caffo O, Doglioni C, et al: p21WAF1 immunohistochemical expression in breast carcinoma: Correlations with clinico-pathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 74:208-215, 1996
17. Ito K, Sasano H, Matsunaga G, et al: Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 183:318-324, 1997
18. Dettmar P, Harbeck N, Thomssen C, et al: Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer 75:1525-1533, 1997
19. Salvesen HB, Iversen OE, Akslen LA: Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer 77:1140-1144, 1998
20. Scott RJ, Hall PA, Haldane JS, et al: A comparison of immunohistochemical markers of cell proliferation with experimentally determined growth fraction. J Pathol 165:173-178, 1991
21. McCormick D, Hall PA: The complexities of proliferating cell nuclear antigen. Histopathology 21:591-594, 1992
22. Cattoretti G, Becker MH, Key G, et al: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357-363, 1992
23. McCormick D, Chong H, Hobbs C, et al: Detection of the Ki-67 antigen in fixed and wax-embedded sections with the monoclonal antibody MIB1. Histopathology 22:355-360, 1993
24. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1989
25. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenetic switch during tumorigenesis. Cell 86:353-364, 1996
26. Weidner N: Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 147:9-19, 1995
27. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-153, 1995
28. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
29. Vile RG: p53: A gene for all tumours? BMJ 307:1226-1227, 1993 (editorial)
30. Gartel AL, Serfas MS, Tyner AL: p21-negative regulator of the cell cycle. Proc Soc Exp Biol Med 213:138-149, 1996
31. El-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
32. Bukholm IK, Nesland JM, Kåresen R, et al: Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181:140-145, 1997
33. Dameron KM, Volpert OV, Tainsky MA, et al: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994
34. The Cancer Registry of Norway: Cancer in Norway 1992. Oslo, Norway, Institute for Epidemiological Cancer Research, 1995
35. Mikuta JJ: International Federation of Gynecology and Obstetrics staging of endometrial cancer 1988. Cancer 71:1460-1463, 1993
36. Scully RE, Bonfiglio TA, Kurman RJ, et al: Histological typing of female genital tract tumours. International histological classification of tumours. Berlin, Germany, World Health Organization, Springer-Verlag, 1994
37. Cox DR: Regression models and life-tables. J R Stat Soc 34:187-220, 1972
38. Norusis MJ: SPSS Advanced Statistics 6.1. Chicago, IL, SPSS Inc, 1994
39. Hendrickson M, Ross J, Eifel PJ, et al: Adenocarcinoma of the endometrium: Analysis of 256 cases with carcinoma limited to the uterine corpus. Gynecol Oncol 13:373-392, 1982
40. Salvesen HB, Akslen LA, Albrektsen G, et al: Poorer survival for nulliparous women with endometrial carcinoma. Cancer 82:1328-1333, 1998
41. Wagenius G, Bergström R, Strang P, et al: Prognostic significance of flow cytometric and clinical variables in endometrial adenocarcinoma stages I and II. Anticancer Res 12:725-732, 1992
42. Kaleli S, Kosebay D, Bese T, et al: A strong prognostic variable in endometrial carcinoma: Flow cytometric S-phase fraction. Cancer 79:944-951, 1997
43. Strang P, Nordström B, Nilsson S, et al: Mutant p53 protein as a predictor of survival in endometrial carcinoma. Eur J Cancer 32A:598-602, 1996
44. Stendahl U, Strang P, Wagenius G, et al: Prognostic significance of proliferation in endometrial adenocarcinomas: A multivariate analysis of clinical and flow cytometric variables. Int J Gynecol Pathol 10:271-284, 1991
45. Pfisterer J, Kommoss F, Sauerbrei W, et al: Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecol Oncol 58:149-156, 1994
46. Podratz KC, Wilson TO, Gaffey TA, et al: Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol 168:1206-1215, 1993
47. Sorbe B, Risberg B, Thornthwaite J: Nuclear morphometry and DNA flow cytometry as prognostic methods for endometrial carcinoma. Int J Gynecol Cancer 4:94-100, 1994
48. Frierson HF Jr: The need for improvement in flow cytometric analysis of ploidy and S-phase fraction. Am J Clin Pathol 95:439-441, 1991
49. Thornton JG, Ali S, O'Donovan P, et al: Flow cytometric studies of ploidy and proliferative indices in the Yorkshire trial of adjuvant progestogen treatment of endometrial cancer. Br J Obstet Gynaecol 100:253-261, 1993
50. Salvesen HB, Iversen OE, Akslen LA: Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 4:2779-2785, 1998
51. Gassel AM, Backe J, Krebs S, et al: Endometrial carcinoma: Immunohistochemically detected proliferation index is prognosticator of long term outcome. J Clin Pathol 51:25-29, 1998
52. Geisler JP, Wiemann MC, Zhou Z, et al: Proliferation index determined by MIB-1 and recurrence in endometrial cancer. Gynecol Oncol 61:373-377, 1996
53. Nielsen AL, Nyholm HC: Proliferative activity as revealed by Ki-67 in uterine adenocarcinoma of endometrioid type: Comparison of tumours from patients with and without previous oestrogen therapy. J Pathol 171:199-205, 1993
54. Kaku T, Kamura T, Kinukawa N, et al: Angiogenesis in endometrial carcinoma. Cancer 80:741-747, 1997
55. Baillie CT, Winslet MC, Bradley NJ: Tumour vasculature: A potential therapeutic target. Br J Cancer 72:257-267, 1995
56. Sherman ME, Bur ME, Kurman RE: p53 in endometrial cancer and its putative precursors: Evidence of diverse pathways of tumorigenesis. Hum Pathol 26:1269-1274, 1995
57. Reinartz JJ, George E, Lindgren BR, et al: Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 25:1075-1083, 1994
58. Tashoiro H, Isacson C, Levine R, et al: p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150:177-185, 1997
59. Moll UM, Chalas E, Auguste M, et al: Uterine papillary serous carcinoma evolves via a p53 driven pathway. Hum Pathol 27:1295-1300, 1996
60. Kohlberger P, Gitsch G, Loesch A, et al: p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol 62:213-217, 1996
61. Lukes AS, Kohler MF, Pieper CF, et al: Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial carcinoma. Cancer 73:2380-2385, 1994
62. Inoue M, Okayama A, Fujita M, et al: Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int J Cancer 58:14-19, 1994
63. Geisler JP, Wiemann MC, Zhou Z, et al: P53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 61:245-248, 1996
64. Soong R, Knowles S, Williams KE, et al: Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 74:562-567, 1996
65. Pisani AL, Barbuto DA, Chen D, et al: HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85:729-734, 1995
66. Hamel NW, Sebo TJ, Wilson TO, et al: Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 62:192-198, 1996
67. Matthews RP, Hutchinson-Colas J, Maiman M, et al: Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. Gynecol Oncol 65:206-212, 1997
68. Clifford SL, Kaminetsky CP, Cirisano FD, et al: Racial disparity in overexpression of the p53 tumor suppressor gene in stage I endometrial cancer. Am J Obstet Gynecol 176:229-232, 1997
69. Palazzo JP, Mercer WE, Kovatich AJ, et al: Immunohistochemical localization of p21(WAF1/CIP1) in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 28:60-66, 1997